How do neurological disorders arise that are caused, triggered, or influenced by antibodies? What better possibilities are there for diagnosis – and above all for treatment? These are the questions addressed by the new Clinical Research Unit “BecauseY” headed by Charité – Universitätsmedizin Berlin. Innovative treatment options will especially benefit patients who at first glance are not suspected of having an antibody-mediated neurological disease.
To lower drug prices, White House takes new aim at pharma patents
WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to claw back patents for certain high-priced medicines,
December 6, 2023